Bavarian Nordic Receives U.S. FDA Approval of Chikungunya Vaccine for Persons Aged 12 and Older
First chikungunya vaccine approved for persons as young as 12 years old, addressing an unmet need for chikungunya prevention for younger ...
Bavarian Nordic gets FDA approval for chikungunya vaccine
Bavarian Nordic (OTCPK:BVNRY) has received FDA approval for its vaccine Vimkunya for the prevention of chikungunya. The virus-like particle, or VLP, vaccine is approved for people aged 12 and older.
Medscape21h
Rapid and Real-time Assays for Detection and Quantification of Chikungunya Virus
A definitive diagnosis of Chikungunya infection can be made only with the aid of laboratory support since clinically, symptoms resemble those of dengue fever. Laboratory diagnosis is therefore ...